177 related articles for article (PubMed ID: 15038960)
21. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
Speroff L
Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
[TBL] [Abstract][Full Text] [Related]
22. A unifying mechanism in the initiation of cancer and other diseases by catechol quinones.
Cavalieri EL; Rogan EG
Ann N Y Acad Sci; 2004 Dec; 1028():247-57. PubMed ID: 15650250
[TBL] [Abstract][Full Text] [Related]
23. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
24. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
25. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
26. Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism.
Cavalieri EL; Rogan EG; Chakravarti D
Cell Mol Life Sci; 2002 Apr; 59(4):665-81. PubMed ID: 12022473
[TBL] [Abstract][Full Text] [Related]
27. A unified mechanism in the initiation of cancer.
Cavalieri EL; Rogan EG
Ann N Y Acad Sci; 2002 Apr; 959():341-54. PubMed ID: 11976208
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
29. Discovery of thiochroman and chroman derivatives as pure antiestrogens and their structure-activity relationship.
Kanbe Y; Kim MH; Nishimoto M; Ohtake Y; Kato N; Tsunenari T; Taniguchi K; Ohizumi I; Kaiho S; Morikawa K; Jo JC; Lim HS; Kim HY
Bioorg Med Chem; 2006 Jul; 14(14):4803-19. PubMed ID: 16580210
[TBL] [Abstract][Full Text] [Related]
30. [Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?].
Ringa V; Fournier A
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):297-301. PubMed ID: 18947946
[No Abstract] [Full Text] [Related]
31. Drug interaction with estrogen receptors for the control of breast neoplasia (review).
Leclercq G; Heuson JC
Anticancer Res; 1981; 1(4):217-28. PubMed ID: 7049050
[No Abstract] [Full Text] [Related]
32. The use of HRT in patients with breast cancer: yes, no, or sometimes?
Stebbing J; Gregory RK
Br J Gen Pract; 2000 May; 50(454):356, 359. PubMed ID: 10897530
[No Abstract] [Full Text] [Related]
33. Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor.
Lloyd DG; Hughes RB; Zisterer DM; Williams DC; Fattorusso C; Catalanotti B; Campiani G; Meegan MJ
J Med Chem; 2004 Nov; 47(23):5612-5. PubMed ID: 15509159
[TBL] [Abstract][Full Text] [Related]
34. Tyrosinase-catalyzed oxidation of 17beta-estradiol: structure elucidation of the products formed beyond catechol estrogen quinones.
Pezzella A; Lista L; Napolitano A; d'Ischia M
Chem Res Toxicol; 2005 Sep; 18(9):1413-9. PubMed ID: 16167833
[TBL] [Abstract][Full Text] [Related]
35. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
36. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
37. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
38. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer.
Ho SM; Leung YK; Chung I
Ann N Y Acad Sci; 2006 Nov; 1089():177-93. PubMed ID: 17261766
[TBL] [Abstract][Full Text] [Related]
39. Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers.
Cavalieri EL; Rogan EG
Future Oncol; 2010 Jan; 6(1):75-91. PubMed ID: 20021210
[TBL] [Abstract][Full Text] [Related]
40. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer.
Dimitrov NV; Colucci P; Nagpal S
Oncologist; 2007 Jul; 12(7):798-807. PubMed ID: 17673611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
